<DOC>
	<DOCNO>NCT00472771</DOCNO>
	<brief_summary>The purpose study determine whether INNO-206 effective treatment small cell lung cancer .</brief_summary>
	<brief_title>INNO-206 Patients With Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description>This phase II , open-label , prospective , multicenter , single-arm study INNO 206 adult patient recurrent extensive small cell lung cancer sensitive first-line platinum-based therapy . The primary objective study determine objective overall response rate . Secondary objective include evaluate treatment-related toxicity patient population determine pharmacokinetic ( PK ) profile INNO-206 minimum 12 patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Be ≥18 year old . Have histologically cytologically confirm diagnosis recurrent extensive small cell lung cancer ( SCLC ) time enrollment study . Have respond firstline platinumbased chemotherapy , progress relapse ≥60 day completion firstline therapy . Have measurable disease define RECIST . Have Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 . Have estimate life expectancy ≥4 week . Be male nonpregnant , nonlactating female patient . Patients fertile must agree use effective barrier method birth control avoid pregnancy therapy 90 day follow discontinuation study medication . Have negative serum urine pregnancy test within 7 day prior first dose study medication ( patient female childbearing potential ) . Have adequate organ function . Are pregnant lactating . Have receive prior anthracycline therapy . Have participate investigational drug study within 30 day prior study entry . Have receive radiotherapy within 2 week treatment study . Have recover acute toxicity previous therapy prior enrollment . Have history malignancy SCLC . Exceptions include : curatively treat nonmelanomatous carcinoma skin situ carcinoma cervix , prior lowgrade , localized prostate cancer ( Gleason score ≤6 ) ; history another malignancy curatively treat evidence recurrence minimum 5 year . Have symptomatic central nervous system ( CNS ) metastasis . Have concurrent severe uncontrolled medical disease ( active systemic infection , hypertension , congestive heart failure ≥NYHA Grade II , myocardial infarction within 6 month study start , severe rhythm disturbance , etc . ) , opinion Investigator , would compromise safety patient compromise ability patient complete study . Have psychiatric disorder ( ) would interfere consent , study participation , followup . Have receive radiotherapy &gt; 25 % involvement bone marrow within 6 week prior study start . Have know hypersensitivity doxorubicin , 5 % D ( + ) sucrose , 10 mM sodium phosphate , and/or 0.3 % Nacetyltryptophane .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Recurrent extensive small cell lung cancer</keyword>
</DOC>